WFDC2 and interstitial lung disease: In summary, our findings showed a novel role of HE4 in RA risk stratification, suggesting that introducing HE4 to the current RA test panel (i.e., anti-CCP and RF) may provide additional diagnostic value to the current clinically available assays, especially in identifying RA patients for further RA-ILD workups, such as HRCT.